Search Result

Results for "

SAR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) 5-HT Receptor (1) AAK1 (2) ADC Linker (1) Akt (2) Amino Acid Derivatives (6) Angiotensin Receptor (6) Angiotensin-converting Enzyme (ACE) (6) Antibiotic (12) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (27) Autophagy (27) Bacterial (15) Bcr-Abl (2) Biochemical Assay Reagents (1) Bradykinin Receptor (1) Btk (2) c-Fms (1) c-Kit (2) c-Met/HGFR (1) Calcium Channel (2) Casein Kinase (3) Cathepsin (16) CCR (1) CDK (1) Ceramidase (1) Cholinesterase (ChE) (2) Complement System (1) COX (4) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (8) Dengue virus (2) Deubiquitinase (2) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (2) DNA/RNA Synthesis (14) Dopamine Receptor (6) Drug Metabolite (6) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (9) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (1) FAAH (1) Factor Xa (2) Fatty Acid Synthase (FASN) (2) Ferroptosis (1) Filovirus (3) Flavivirus (2) Fluorescent Dye (1) Fungal (2) FXR (1) G-quadruplex (1) GCGR (3) GLP Receptor (3) Glucosylceramide Synthase (GCS) (3) Glutathione Peroxidase (1) GSK-3 (1) HBV (1) HCV (27) HCV Protease (17) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (11) Histone Methyltransferase (5) HIV (36) HIV Protease (21) HSP (1) HSV (3) Influenza Virus (12) Integrin (2) Interleukin Related (4) Isotope-Labeled Compounds (30) JAK (3) Keap1-Nrf2 (3) Lipoxygenase (1) LPL Receptor (2) MAGL (2) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (1) Mitophagy (1) MMP (4) Monoamine Oxidase (1) mTOR (1) Myosin (4) nAChR (1) Neurokinin Receptor (7) Neuropeptide Y Receptor (1) NF-κB (3) NOD-like Receptor (NLR) (1) Notch (1) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (2) Orthopoxvirus (1) P-glycoprotein (5) PAI-1 (1) Parasite (31) PDGFR (2) Phosphatase (2) PI3K (6) PKC (2) Potassium Channel (2) PROTACs (3) Ras (1) Reactive Oxygen Species (2) Reverse Transcriptase (2) RIP kinase (1) ROCK (2) ROS Kinase (2) RSV (2) SARS-CoV (458) Ser/Thr Protease (10) Sigma Receptor (3) Sirtuin (3) Small Interfering RNA (siRNA) (5) Sodium Channel (7) STING (9) Telomerase (1) Thrombin (2) TNF Receptor (1) Toll-like Receptor (TLR) (18) Topoisomerase (2) Trk Receptor (1) TRP Channel (3) VEGFR (3) Virus Protease (21)
By Research Areas:	Cancer (108) Cardiovascular Disease (23) Endocrinology (15) Infection (444) Inflammation/Immunology (76) Metabolic Disease (35) Neurological Disease (29)

By Targets:

11β-HSD (3)

5-HT Receptor (1)

AAK1 (2)

ADC Linker (1)

Akt (2)

Amino Acid Derivatives (6)

Angiotensin Receptor (6)

Angiotensin-converting Enzyme (ACE) (6)

Antibiotic (12)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (27)

Autophagy (27)

Bacterial (15)

Bcr-Abl (2)

Biochemical Assay Reagents (1)

Bradykinin Receptor (1)

Btk (2)

c-Fms (1)

c-Kit (2)

c-Met/HGFR (1)

Calcium Channel (2)

Casein Kinase (3)

Cathepsin (16)

CCR (1)

CDK (1)

Ceramidase (1)

Cholinesterase (ChE) (2)

Complement System (1)

COX (4)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (8)

Dengue virus (2)

Deubiquitinase (2)

Dihydroorotate Dehydrogenase (1)

DNA Methyltransferase (2)

DNA/RNA Synthesis (14)

Dopamine Receptor (6)

Drug Metabolite (6)

E1/E2/E3 Enzyme (1)

EGFR (1)

Endogenous Metabolite (9)

Estrogen Receptor/ERR (1)

Eukaryotic Initiation Factor (eIF) (1)

FAAH (1)

Factor Xa (2)

Fatty Acid Synthase (FASN) (2)

Ferroptosis (1)

Filovirus (3)

Flavivirus (2)

Fluorescent Dye (1)

Fungal (2)

FXR (1)

G-quadruplex (1)

GCGR (3)

GLP Receptor (3)

Glucosylceramide Synthase (GCS) (3)

Glutathione Peroxidase (1)

GSK-3 (1)

HBV (1)

HCV (27)

HCV Protease (17)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (11)

Histone Methyltransferase (5)

HIV (36)

HIV Protease (21)

HSP (1)

HSV (3)

Influenza Virus (12)

Integrin (2)

Interleukin Related (4)

Isotope-Labeled Compounds (30)

JAK (3)

Keap1-Nrf2 (3)

Lipoxygenase (1)

LPL Receptor (2)

MAGL (2)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (1)

Mitophagy (1)

MMP (4)

Monoamine Oxidase (1)

mTOR (1)

Myosin (4)

nAChR (1)

Neurokinin Receptor (7)

Neuropeptide Y Receptor (1)

NF-κB (3)

NOD-like Receptor (NLR) (1)

Notch (1)

Nucleoside Antimetabolite/Analog (1)

Opioid Receptor (2)

Orthopoxvirus (1)

P-glycoprotein (5)

PAI-1 (1)

Parasite (31)

PDGFR (2)

Phosphatase (2)

PI3K (6)

PKC (2)

Potassium Channel (2)

PROTACs (3)

Ras (1)

Reactive Oxygen Species (2)

Reverse Transcriptase (2)

RIP kinase (1)

ROCK (2)

ROS Kinase (2)

RSV (2)

SARS-CoV (458)

Ser/Thr Protease (10)

Sigma Receptor (3)

Sirtuin (3)

Small Interfering RNA (siRNA) (5)

Sodium Channel (7)

STING (9)

Telomerase (1)

Thrombin (2)

TNF Receptor (1)

Toll-like Receptor (TLR) (18)

Topoisomerase (2)

Trk Receptor (1)

TRP Channel (3)

VEGFR (3)

Virus Protease (21)

By Research Areas:

Cancer (108)

Cardiovascular Disease (23)

Endocrinology (15)

Infection (444)

Inflammation/Immunology (76)

Metabolic Disease (35)

Neurological Disease (29)

604

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

SAR-020106
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC₅₀ of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .

SAR-260301	PI3K	Cancer
SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC₅₀ of 23 nM .

SAR405 R enantiomer	Others	Cancer
SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is a PIK3C3/Vps34 inhibitor.

*(Sar1)-Angiotensin II*	Angiotensin Receptor	Cardiovascular Disease
(Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. (Sar1)-Angiotensin II binds to brain membrane-rich particles, with a K_d of 2.7 nM. (Sar1)-Angiotensin II can stimulate protein synthesis and cell growth in embryonic chick myocytes .

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC₅₀ of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

SAR-20347 1 Publications Verification	JAK	Cancer
SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC₅₀s of 0.6, 23, 26 and 41 nM, respectively.

SAR629	MAGL	Metabolic Disease
SAR629 is a potent monoglyceride lipase (MGL) covalent inhibitor. SAR629 also inhibits 2-Arachidonoylglycerol (2-AG) degradation .

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

SAR125844	c-Met/HGFR PI3K Akt MEK Apoptosis	Cancer
SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC₅₀ is 4.2 nM and K_i is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer .

SAR131675 5+ Cited Publications	VEGFR	Cancer
SAR131675 is a potent and selective VEGFR3 inhibitor with an IC₅₀ of 23 nM. SAR131675 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

SAR407899 2 Publications Verification	ROCK	Metabolic Disease
SAR407899 is a selective, potent and ATP-competitive ROCK inhibitor, with an IC₅₀ of 135 nM for ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2, respectively. SAR407899 shows stable inhibition of migrasome formation.

SAR441255 TFA	GLP Receptor	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

Amcenestrant 1 Publications Verification SAR439859	Estrogen Receptor/ERR	Cancer
SAR439859 (compound 43d) is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD). SAR439859 is a potent ER antagonist and has ER degrading activity with an EC₅₀ of 0.2 nM for ERα degradation . SAR439859 demonstrates robust antitumor efficacy and limited cross-resistance in ER ⁺ breast cancer .

SAR405838 MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

Sar-Pro-Arg-pNA	Thrombin	Cardiovascular Disease
Sar-Pro-Arg-pNA is a chromogenic substrate of α-thrombin. Sar-Pro-Arg-pNA can be used to test α-thrombin activity .

SAR7334 hydrochloride 10+ Cited Publications	TRP Channel	Neurological Disease
SAR7334 hydrochloride is a potent and specific TRPC6 inhibitor, inhibiting TRPC6 currents with IC₅₀ of 7.9 nM.

SAR7334 10+ Cited Publications	TRP Channel	Neurological Disease
SAR7334 is a potent and specific TRPC6 inhibitor, inhibiting TRPC6 currents with IC₅₀ of 7.9 nM.

SAR405 15+ Cited Publications	PI3K Autophagy	Cancer
SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform Vps34 inhibitor (IC₅₀=1.2 nM; K_d=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity .

SAR107375	Thrombin	Metabolic Disease
SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with K_i values of 1 nM and 8 nM for factor Xa and thrombin, respectively .

SARS-CoV-2 Mpro-IN-3	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-3 is a potent M ^pro inhibitor with an IC₅₀ value of ﹥5 μM. SARS-CoV-2 Mpro-IN-3 can be used in research of COVID-19 .

*(Sar1,Ile4,8)-Angiotensin II*	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .

Atuzabrutinib SAR 444727; PRN473	Btk	Inflammation/Immunology
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .

Romilkimab SAR156597	Interleukin Related	Others
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .

SAR407899 hydrochloride 2 Publications Verification	ROCK	Metabolic Disease
SAR407899 hydrochloride is a selective, potent and ATP-competitive ROCK inhibitor, with an IC₅₀ of 135 nM for ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2, respectively.

SARS-CoV-2-IN-38	SARS-CoV	Infection
SARS-CoV-2-IN-38 (compound 24) is a *SARS-CoV-2* inhibitor with good oral bioavailability in mice (F%=39.75%) .

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

SAR1A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SAR1A Human Pre-designed siRNA Set A contains three designed siRNAs for SAR1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SARS 3CLpro-IN-1	SARS-CoV	Cancer
SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC₅₀ value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .

SAR1B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SAR1B Human Pre-designed siRNA Set A contains three designed siRNAs for SAR1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lifitegrast 2 Publications Verification SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast sodium 2 Publications Verification SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

Frexalimab SAR441344; INX-021	TNF Receptor	Inflammation/Immunology
Frexalimab (SAR441344; INX-021) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab has the potential for multiple sclerosis research .

SARS-CoV-2-IN-61	SARS-CoV	Infection
SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC₅₀ of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .

Saralasin acetate hydrate [SAR1,Ala8] Angiotensin II acetate hydrate	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

Saralasin [SAR1,Ala8] Angiotensin II
Saralasin ([Sar1,Ala8] Angiotensin II) is an octapeptide analog of angiotensin II. Saralasin is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

Sar-[D-Phe8]-des-Arg9-Bradykinin	Bradykinin Receptor	Inflammation/Immunology Endocrinology
Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .

Quisovalimab AVTX-002; AEVI 002; SAR 252067	SARS-CoV	Cardiovascular Disease
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .

Saralasin TFA [SAR1,Ala8] Angiotensin II TFA	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

Pilaralisib 3 Publications Verification XL-147; SAR245408	PI3K	Cancer
Pilaralisib (XL147; SAR245408) is a potent and highly selective class I PI3Ks inhibitor with IC₅₀s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

Tolebrutinib 2 Publications Verification SAR442168; PRN2246	Btk	Neurological Disease
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with IC₅₀s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS) .

SAR247799 S1P1 agonist 3	LPL Receptor	Cardiovascular Disease
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC₅₀s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome .

Cat. No.	Product Name

HY-L002

Anti-Infection Compound Library

2882 compounds

An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents.

MCE provides a unique collection of 2882 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

HY-L113

Antiviral Traditional Chinese Medicine Active Compound Library

171 compounds

Increasing research have shown that Traditional Chinese Medicine (TCM) possess antiviral activities against various viral strains, such as herpes simplex virus, influenza virus, hepatitis B and C viruses, and SARS-CoV. To date, dozens of Chinese herbs and hundreds of natural TCM ingredients have been reported to exhibit good antiviral activities. Active components from TCM are one of the important sources for antiviral drugs discovery.

MCE designs a unique collection of 171 active compounds of antiviral Chinese Herbal Medicines. MCE Antiviral Traditional Chinese Medicine Active Compound Library is a useful tool for discovery antiviral drugs from TCM.

HY-L027

Antiviral Compound Library

1270 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Type

HY-D1270

Direct Violet 1	Dyes
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC₅₀s of 1.47-2.63 μM .

Cat. No.	Product Name	Target	Research Area

HY-P3138

*(Sar1)-Angiotensin II*	Angiotensin Receptor	Cardiovascular Disease
(Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. (Sar1)-Angiotensin II binds to brain membrane-rich particles, with a K_d of 2.7 nM. (Sar1)-Angiotensin II can stimulate protein synthesis and cell growth in embryonic chick myocytes .

HY-P10031A

SAR441255 TFA	GLP Receptor	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

HY-P4475

Sar-Pro-Arg-pNA

Thrombin Cardiovascular Disease

Sar-Pro-Arg-pNA is a chromogenic substrate of α-thrombin. Sar-Pro-Arg-pNA can be used to test α-thrombin activity .

HY-P4685

*(Sar1,Ile4,8)-Angiotensin II*	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .

HY-P0205A

Saralasin acetate hydrate [SAR1,Ala8] Angiotensin II acetate hydrate	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-103291

Sar-[D-Phe8]-des-Arg9-Bradykinin	Bradykinin Receptor	Inflammation/Immunology Endocrinology
Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .

HY-P0205B

Saralasin TFA [SAR1,Ala8] Angiotensin II TFA	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P4166

Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar	Peptides	Cancer
Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar is a decapeptide. Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar can be used to preparation of antibody-drug conjugate .

HY-P4296

*H-Gly-Sar-Sar-OH*	Amino Acid Derivatives	Others
H-Gly-Sar-Sar-OH is an orally active tripeptide. H-Gly-Sar-Sar-OH is transported through PepT1 within Caco-2 cells. H-Gly Sar Sar OH has potential applications in material transportation .

HY-P3801

*[Glp5,(Me)Phe8,Sar9] Substance P (5-11)* DiMe-C7	Neurokinin Receptor	Others Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

HY-W010276

Gly-Sar

GlycylSARcosine
Amino Acid Derivatives Others

Gly-Sar is a Glycine (HY-Y0966) derivative .
HY-W015230

Boc-Sar-OH

Amino Acid Derivatives Others

Boc-Sar-OH is a Glycine (HY-Y0966) derivative .
HY-W011342

Fmoc-Sar-OH

Amino Acid Derivatives Others

Fmoc-Sar-OH is a Glycine (HY-Y0966) derivative .
HY-W013517

Z-Sar-OH

Amino Acid Derivatives Others

Z-Sar-OH is a Glycine (HY-Y0966) derivative .
HY-W018062

H-Sar-OtBu.HCl

Amino Acid Derivatives Others

H-Sar-OtBu.HCl is a Glycine (HY-Y0966) derivative .
HY-P1738

[Sar9] Substance P

Neurokinin Receptor Neurological Disease Endocrinology

[Sar9] Substance P is a potent and selective neurokinin (NK)-1 receptor agonist .
HY-P1012

[Sar9,Met(O2)11]-Substance P

Neurokinin Receptor Neurological Disease Endocrinology

[Sar9,Met(O2)11]-Substance P is a tachykinin NK₁ receptor selective agonist.
HY-P3905

[Glp5,Sar9] Substance P (5-11)

Neurokinin Receptor Neurological Disease

[Glp5,Sar9] Substance P (5-11) is an analogue of Substance P (HY-P0201) .
HY-P4198

Fmoc-N(Me)-Sar10

Biochemical Assay Reagents Others

Fmoc-N(Me)-Sar10 can be used for synthesis of peptide ligand-agent conjugates .
HY-P1012A

[Sar9,Met(O2)11]-Substance P TFA

Neurokinin Receptor Neurological Disease Endocrinology

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK₁ receptor selective agonist.

HY-P1564

*[Sar1, Ile8]-Angiotensin II*	Angiotensin Receptor	Cardiovascular Disease Endocrinology
[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

HY-P3932

*[Sar4] Substance P (4-11)*	Neurokinin Receptor	Neurological Disease
[Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist .

HY-P3927

*[MePhe8,Sar9] Substance P* [MePhe8-MeGly9] Substance P	Neurokinin Receptor	Neurological Disease
[MePhe8,Sar9] Substance P ([MePhe8-MeGly9] Substance P) is an analog of Substance P (Substance P (HY-P0201)).Substance P is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS .

HY-160429

PSAR18-COOH	Peptides	Others
PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.

HY-P5975

Z-Leu-Leu-Leu-fluoromethyl ketone Z-LLL-FMK	Cathepsin SARS-CoV	Infection
Z-Leu-Leu-Leu-fluoromethyl ketone (Z-LLL-FMK) is a cysteine protease inhibitor. Z-Leu-Leu-Leu-fluoromethyl ketone inhibits *SARS* infection. Z-Leu-Leu-Leu-fluoromethyl ketone also protects mice against a T. crassiceps challenge .

HY-P1564A

*[Sar1, Ile8]-Angiotensin II TFA* AngiotensinII TFA; Angiotensin 2 TFA	Angiotensin Receptor	Others
[Sar1, Ile8]-Angiotensin II (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

HY-P5398

HR2-18

Peptides Others

HR2-18 is a biological active peptide. (inhibition of SARS-CoV penetration into cells.)
HY-P4388

Z-Arg-Leu-Arg-Gly-Gly-AMC

SARS-CoV Infection

Z-Arg-Leu-Arg-Gly-Gly-AMC is a peptide substrate of SARS-CoV PL ^pro .
HY-P5416

GGASCCLYCRCH

Peptides Others

GGASCCLYCRCH is a biological active peptide. (can inhibit the 2-O-methyltransferase activity of the SARS-CoV complex nsp16/10)

HY-P3258

SP-10	Cholinesterase (ChE)	Infection
SP-10 is a small peptide derived from S protein with an IC₅₀ value of 1.88 nM for blocks the interaction between S protein and ACE2. SP-10 can be used for SARS-CoV research .

HY-18234

Leupeptin	Ser/Thr Protease Virus Protease Cathepsin	Infection Inflammation/Immunology
Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M ^pro (the main protease of *SARS-CoV-2*) and also has anti-inflammatory activity .

HY-P5827

SBP1 peptide	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SBP1 peptide is a chemically synthesized 23-mer peptide fragment of the ACE2 PD α1 helix. SBP1 peptide associates with micromolar affinity to insect-derived *SARS-CoV-2*-RBD protein .

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P4307

Antioxidant agent-9	SARS-CoV	Infection
Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as *SARS-CoV-2* antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768) .

HY-P2296

Abz-FRLKGGAPIKGV-EDDNP TFA	Fluorescent Dye	Others
Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against *SARS-CoV-2* with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-P3626

Astodrimer SPL7013 free base	Bacterial HCV SARS-CoV	Infection
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties .

Cat. No.	Product Name	Target	Research Area

HY-P990091

Riliprubart SAR 445088	Complement System	Inflammation/Immunology
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Inflammation/Immunology
Frexalimab (SAR441344; INX-021) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab has the potential for multiple sclerosis research .

HY-P99431

KY-1044 Alomfilimab; SAR 445256	Inhibitory Antibodies	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-P99810

Quisovalimab AVTX-002; AEVI 002; SAR 252067	SARS-CoV	Cardiovascular Disease
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .

HY-P99883

Romilkimab

SAR156597
Interleukin Related Others

Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P9928

Alirocumab REGN 727; SAR 236553	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia .

HY-P9926

Dupilumab 1 Publications Verification REGN-668; SAR-231893	Interleukin Related	Inflammation/Immunology Cancer
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .

HY-P99434

Amlitelimab KY1005; SAR445229	Inhibitory Antibodies	Inflammation/Immunology
Alvircept sudotox is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Alvircept sudotox inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .

HY-P99673

Itepekimab REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-P9803

Anti-SARS-80R mAb SARS-80R; SARS Antibody-80R	SARS-CoV	Infection
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent *SARS* virus infection of susceptible cells .

HY-P9807

Anti-SARS-CoV-2 Spike mAb (CR3022) SARS-CR3022; SARS-CoV-2 Antibody-CR3022	SARS-CoV	Infection Inflammation/Immunology
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-P9802

Anti-Spike-RBD Single Domain mAb SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

HY-P9801

Anti-Spike-RBD mAb 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD Antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P99423

Adintrevimab 1 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal *SARS-CoV* (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the *SARS-CoV-2* receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P99103

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to *SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS*-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P99347

Etesevimab

CB 6; JS016
SARS-CoV Angiotensin-converting Enzyme (ACE) Infection

Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-145644

Ogalvibart C-135-LS; BMS-986414	SARS-CoV	Infection
Ogalvibart (C-135-LS) is a *human anti-SARS-CoV-2 monoclonal antibody* (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of *SARS-CoV-2*. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .

HY-P99340

Sotrovimab VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-P99104

Plutavimab

COVI-AMG; STI-2020
SARS-CoV Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
HY-P990052

Simaravibart

MAD-0004J08
SARS-CoV Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an *anti-SARS-CoV-2 monoclonal antibody* (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the *SARS-CoV-2* spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an *anti-SARS-CoV-2 monoclonal antibody* (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the *SARS-CoV-2* spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-P99889

Romlusevimab BRII-198	SARS-CoV	Infection
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

HY-145641

Crexavibart BMS-986413; C-144-LS	SARS-CoV	Infection
Crexavibart (BMS-986413; C-144-LS) is an IgG1_λ2 antibody that targets the *SARS-CoV2* spike (S) glycoprotein receptor-binding domain .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P99054

Tusamitamab	Inhibitory Antibodies	Cancer
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of *SARS-CoV-2* spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of *SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀* value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P99376

Narsoplimab OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)	SARS-CoV	Infection
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .

HY-P99012

Clazakizumab	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .

HY-P99342

Imdevimab REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody to target *SARS-CoV-2* virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .

HY-P99341

Casirivimab REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody to target *SARS-CoV-2* virus, which causes COVID-19. Casirivimab lacks efficacy against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), it reduces viral load and improves diseases .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

Species:	Human (3) Staphylococcus aureus (1)
Tag:	His (2) GST (1) Fc (1)
Source:	HEK293 (2) P. pastoris (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72705

	CD82 Protein, Human (HEK293, Fc) CD82 antigen; C33 antigen; Tspan-27; CD82; KAI1; SAR2; ST6; TSPAN27	Human	HEK293
	CD82, a vital immune response participant, engages with CD4 or CD8 to provide crucial costimulatory signals in the TCR/CD3 pathway. Its direct interaction with IGSF8 plays a pivotal role in modulating immune functions and mediating cellular responses. CD82 Protein, Human (HEK293, Fc) is the recombinant human-derived CD82 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CD82 Protein, Human (HEK293, Fc) is 123 a.a., with molecular weight of 40-60 kDa.

HY-P71634

	SAR1A Protein, Human (GST) COPII associated small GTPase; COPII-associated small GTPase; GTP binding protein SAR1a; GTP-binding protein SAR1a; Masra 2; Masra2; SAR 1; SAR1 gene homolog A; SARA 1; SARa; SARA1	Human	E. coli
	The SAR1A protein critically facilitates intracellular transport from the endoplasmic reticulum to the Golgi apparatus. Through SAR1A-GTP-dependent assembly, it organizes endoplasmic reticulum exit sites (ERES), forming a scaffold that defines these sites. SAR1A Protein, Human (GST) is the recombinant human-derived SAR1A protein, expressed by E. coli , with N-GST labeled tag. The total length of SAR1A Protein, Human (GST) is 198 a.a., with molecular weight of ~49.4 kDa.

HY-P71834

	Chemotaxis inhibitory Protein, S. aureus (P.pastoris, His) chp; SAR2036Chemotaxis inhibitory protein; CHIPS	Staphylococcus aureus	P. pastoris
	Chemotaxis Inhibitory Protein (CIP) strategically counters the host defense mechanisms, inhibiting reactions of human neutrophils and monocytes to complement anaphylatoxin C5a and fMLP. As a molecular sentinel, CIP directly engages with C5aR and FPR, obstructing calcium responses induced by C5a and fMLP. In this tactical intervention, CIP acts as a guardian, finessefully thwarting bacterium phagocytosis. Chemotaxis inhibitory Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Chemotaxis inhibitory protein, expressed by P. pastoris , with N-His labeled tag. The total length of Chemotaxis inhibitory Protein, S. aureus (P.pastoris, His) is 121 a.a., with molecular weight of ~16.1 kDa.

HY-P76812

	CD82 Protein, Human (HEK293, His) CD82 antigen; C33 antigen; Tspan-27; CD82; KAI1; SAR2; ST6; TSPAN27	Human	HEK293
	CD82, a vital immune response participant, engages with CD4 or CD8 to provide crucial costimulatory signals in the TCR/CD3 pathway. Its direct interaction with IGSF8 plays a pivotal role in modulating immune functions and mediating cellular responses. CD82 Protein, Human (HEK293, His) is the recombinant human-derived CD82 protein, expressed by HEK293, with C-His labeled tag. The total length of CD82 Protein, Human (HEK293, His) is 118 a.a., with molecular weight of 25-33 kDa.

Cat. No.	Product Name	Chemical Structure

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-109037S2

Mavacamten-d1
Mavacamten-d₁ (MYK461-d₁; SAR439152-d₁) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC₅₀s of 490, 711 nM for bovine cardiac and human cardiac, respectively.

HY-109037S3

Mavacamten-d5
Mavacamten-d₅ (MYK461-d₅; SAR439152-d₅) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC₅₀s of 490, 711 nM for bovine cardiac and human cardiac, respectively.

HY-109037S

Mavacamten-d6
Mavacamten-d₆ (MYK461-d₆; SAR439152-d₆) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC₅₀s of 490, 711 nM for bovine cardiac and human cardiac, respectively.

HY-P5168S

GPSVFPLAPSSK-13C6
GPSVFPLAPSSK- ¹³C₆ is the ¹³C labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-135853S

Molnupiravir-d7

Molnupiravir-d₇ is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-17042AS1

Cetirizine-d8 dihydrochloride
Cetirizine-d₈ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042S

Cetirizine-d4
Cetirizine-d₄ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042S1

Cetirizine-d8
Cetirizine-d₈ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-17007S

Saquinavir-d9
Saquinavir-d₉ is the deuterium labeled Saquinavir. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.36 μM[1][2].

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM[1][2].

HY-B0462AS

Azelastine-13C,d3
Azelastine- ¹³C,d₃ is deuterium labeled Azelastine. Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].

HY-145119S

Mindeudesivir
GS-621763-d₁ is the deuterium labeled GS-621763 (HY-145119) . GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against *SARS-CoV-2* pathogenesis in mice .

HY-B0190S1

Nafamostat formate salt-13C6
Nafamostat formate salt- ¹³C₆ is the ¹³C labeled Nafamostat[1]. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2[2][3][4][5].

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆; rel-RTV-d₆) is the deuterium labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-104077S

Remdesivir-d5 2 Publications Verification
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro[1][2].

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-14904AS

Umifenovir-d6 hydrochloride

Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].

HY-B0462S

Azelastine-13C,d3 hydrochloride
Azelastine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Azelastine hydrochloride. Azelastine- ¹³C,d₃ (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine- ¹³C,d₃ (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-145119AS

Mindeudesivir hydrobromide
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against *SARS-CoV-2* and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .

HY-B1028S

Pantethine-15N2

Pantethine- ¹⁵N₂ is the ¹⁵N₂ labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-Y0189S

Methyl Salicylate-d4

Methyl Salicylate-d₄ is the deuterium labeled Methyl Salicylate[1]. Methyl Salicylate (Wintergreen oil) is a topical analgesic and anti-inflammatory agent. Also used as a pesticide, a denaturant, a fragrance ingredient, and a flavoring agent in food and tobacco products[2]. A systemic acquired resistance (SAR) signal in tobacco[3]. A topical nonsteroidal anti-inflammatory agent (NSAID). Methyl salicylate lactoside is a COX inhibitor[5].

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-14588S1

Lopinavir-d8
Lopinavir-d₈ (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

HY-119980S

Fluphenazine-d8

Fluphenazine-d₈ is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

Cat. No.	Product Name	Application	Reactivity

HY-P81126

PAR1 Antibody SAR; PAR-1; PAR 1; BXR; CF2R; F2R; HTR; TR; Proteinase-activated receptor 1 precursor; Proteinase activated receptor 1; Thrombin receptor; Coagulation factor II receptor; Prader-Willi/Angelman region-1; Coagulation factor II (thrombin) receptor; PAR1_HUMAN	WB; ELISA; IHC-P; IHC-F; IF	Human, Mouse, Rat,
PAR1 Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-PAR1 polyclonal antibody. PAR1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, background without labeling.

HY-P81388

CD82 Antibody (YA1133)

C33; CD82; IA4; Inducible membrane protein; KAI1; Kangai1; SAR2; ST6; Tetraspanin 27; Tspan27
IHC-P Human

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks